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COVID-19 Pandemic – An Apocalypse of Our Time 
Hundreds of coronaviruses naturally circulate in a 
variety of mammals but there are only 7 known 
human coronaviruses which probably originated from 
bats. Four of these viruses 229E, NL63, OC43, and 
HKU1 are endemic that commonly cause relatively 
mild cold-like illnesses while the other 3 have 
caused outbreaks and epidemics namely the SARS-
CoV in 2002-2003, MERS-CoV in 2012 and the SARS-
CoV-2 that is responsible for the current  pandemic 
Covid-19.  The three coronaviruses that caused the 
epidemics belong to the Betacoronavirus genus.1,2 
Both SARS-CoV and SARS-CoV-2 viruses share the 
angiotensin converting enzyme ACE2 as receptor for 
attaching to and infecting pneumocytes in the lungs, 
however, MERS-CoVSARS has a different receptor 
called dipeptidyl peptidase 4 (DPP4 or CD26) found 
in non-ciliated bronchial cells and in kidney cells. 
MERS has the highest case fatality rate of about 30% 
while SARS has a case fatality rate of about 10% and 
CoVid-19 has an estimated crude global fatality rate 
of about 4.6% (26494 deaths/571678 cases) with 
most deaths affecting older age group and those 
with risk factors. As for the ability of person to 
person spread, MERS has the lowest potential and 
CoVid-19 the highest. 2,3  
 
A plethora of research articles, editorials and 
reports have already been published about this novel 
coronavirus appropriately designated as SARS-CoV-2 
which seems to have suddenly emerged from bats as 
reservoir host and infected the pangolin as an 
intermediate mammalian host, that is considered as 
a delicacy in China, from which it probably infected 
humans and successfully maintained itself by human 
to human transmission with an estimated rate of 
transmission of infection (R0) of about 2.2 in a naïve 
population with no immunity.4  This implies that 
once the infection is established in a community 
where random transmission occurs, it will follow a 
logistic model  curve where it spreads  exponentially 
by a certain factor unless prompt effective  
measures are taken to interrupt the chain of 
transmission or a large proportion of the population 
become immune (herd immunity) as a result of 
infection or vaccination.  Since a vaccine is not yet 
available, only transmission chain interruption 
measures will mitigate the epidemic by flattening 
and broadening the peak of the COVID-19 curve and 
thus lessen the disruptive impact on the community. 
This provides the health services time to prepare and 
continue functioning without being overwhelmed. It 
will also provide scientists and clinical investigators 
sufficient critical time for the development and 
testing of therapeutic drugs and vaccines.   
 
However, containing the infection and aborting the 
epidemic requires immediate drastic measures as 
successfully demonstrated in China by active 
detection and tracing infections and interrupting all 
man-to-man transmission by strict quarantine and 
disinfection measures at multiple levels. Similar 
measures were successful in not only curtailing but 
also in eradicating the SARS epidemic within 2 years. 
Although the heaviest toll by cumulative number of 
confirmed cases and deaths was initially in China, 
the USA and western Europe have now exceeded 
China as the new epicenters of the infection while 
other countries are still struggling with the rapidly 
rising number of confirmed cases and associated 
mortalities. This situation is mainly due to delays in 
the authority’s reaction to the pandemic. The delays 
were probably driven mainly by fear of economic 
losses but unfortunately it has caused and will 
continue to cause not only more economic losses but 
more importantly loss of precious human lives.  
 
The variably reported fatality rates by different 
countries until now are not representative of true 
‘case fatality’ rates due to the lack or limited active 
mass screening that will allow detection of mild or 
subclinical infections. Thus, much higher mortality 
rates are reported in countries like Italy as compared 
to S. Korea where more active mass screening tests 
were employed. Differences in fatality rates may also 
be due to variation in virulence of the virus strains 
but this requires further verification. Mass screening 
by the relatively expensive and labor-intensive 
nucleic acid amplification assays would detect new 
cases and provide valuable information about the 
incidence of the disease. The relatively less 
expensive and automated serological tests would 
supply further important information about the 
epidemiology of the disease, but reliable approved 
tests are not yet commercially available.  
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COVID-19 should be taken extremely seriously by all 
countries and all groups and individuals. As of 30th 
March, the total number of cases worldwide had 
exceeded 737,900 with >35,000 deaths. In Malaysia, 
the total number of confirmed cases is steadily rising 
and stands at more than 2000. Nationwide movement 
control order is currently in force till 14th April, 2020.   
 
WHO has also nicknamed the COVID-19 pandemic as 
“Infodemic” due to the widespread misinformation 
and sometimes incorrect data or interpretation of 
data.  The abrupt emergence and spread of the virus 
since December 2019 have raised speculations among 
the public and even scientific media as to its origin 
and timing. There are plenty of stories and views 
about conspiracies related to biological warfare 
research in USA and China as means for destroying 
the economy and hence weakening political and 
military power. These baseless views have been and 
are still expressed and circulating in the news and 
social media. Although bioengineered weapons of 
mass disruption ‘if not destruction’ is a realistic 
worry that has been made more plausible and 
relatively easily practicable with the current huge 
advances in biotechnology, one should not overlook 
the fact that microorganisms like viruses and bacteria 
are better genetic engineers than molecular 
biologists as can be depicted from history. Many of 
these organisms can adapt, overcome new constraints 
on their successful survival and propagation and even 
jump to new hosts by modifying their genomes 
through mutations and genetic recombination. The 
SARS-CoV-2 virus has already undergone mutations 
within a short time since its first appearance in the 
epicenter Wuhan in mainland China.  The two SNP 
(single nucleotide polymorphism) types are labeled         
L and S with differences in prevalence and 
pathogenicity. 2 
 
In conclusion the COVID-19 pandemic is still 
controllable, although not containable for most 
countries. This requires global political, social and 
personal commitment to take appropriate measures 
to stop the chain of transmission. Knowing the mode 
of transmission which is mainly by droplet infection 
that travel short distances of not more than 2 
meters, more recent research has shown some 
worrying data that the virus can survive on surfaces 
for periods ranging from hours to days and that the 
virus may remain viable as airborne droplet nuclei for 
a period of few hours which may explain the relative 
ease with which it spreads.4 These data would entail 
paying more attention at the importance of personal 
hygiene and modifying personal habits, increasing 
frequency of sanitizing or disinfecting surfaces, 
abolishing gatherings and minimizing socialization 
and unnecessary travel especially by public 
transport. These measures probably need to be 
propagated and continued for the near future even 
in countries where the epidemic has subsided 
because of the fear of reintroduction and respread 
especially if a new naturally modified strain of the 
virus emerges. 
 
Vaccine candidates are under development utilizing 
reverse vaccinology (in silico) and machine learning 
tools to predict the components of the viral 
proteome that would serve as safe and effective 
vaccines.5 Also various known antiviral drugs that 
interfere with the function of the viral RNA-
dependent RNA-polymerase, protease inhibitors that 
affect the cleavage of the viral polyprotein into 
functional polypeptides and the antimalarial drug 
hydroxychloroquine that interfere with early phases 
of the viral replication  have been tested and were 
found to be effective in in-vitro studies. Currently 
some of these agents are directly subjected to 
clinical trials as they are previously known and 
approved drugs for other infections.6 Convalescent 
serum from recovered patients has also been shown 
to protect cultured cells from infection and may also 
be effective in vivo if available. However, antiviral 
drugs for COVID-19 as is the case with other known 
respiratory viral infections such as influenza 
probably need to be given early to beneficially alter 
the course of the disease. Addition of drugs that 
suppress the ‘cytokine storm’ in ARDS patients are 
also been considered.  
 
There is no magic pill. It will take several months for 
a reliable and effective vaccine to be developed and 
at least a year for it to be available for mass use. 
This pandemic in the interim can result in a global 
apocalypse as evidenced by its adverse impact not 
only on the health sector but crucially on the 
socioeconomic status worldwide from the most 
affluent to the poorest of nations.  
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